<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449149</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 01310</org_study_id>
    <nct_id>NCT01449149</nct_id>
  </id_info>
  <brief_title>Proton Radiation for Chordomas and Chondrosarcomas</brief_title>
  <official_title>Proton Radiation For Chordomas and Chondrosarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are 1) To evaluate the feasibility and acute side effects of
      proton therapy for chordomas and chondrosarcomas and 2) To evaluate clinical outcomes and
      long term side effects of proton beam radiation for treatment of chordomas and
      chondrosarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be conducted in two phases: a feasibility then a phase II trial. Once
      feasibility and safety are established in the first 12 pts. the phase II study will begin.
      Proton therapy at standard doses is not known to improve clinical outcome but will likely
      reduce fatigue and toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of proton RT for chordomas and chondrosarcomas</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Treatment completion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>Any grade 3 or higher toxicity observed within 90 days from start of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>Any grade 3 or higher toxicty observed later than 90 days from completion of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chordomas</condition>
  <condition>Chondrosarcomas</condition>
  <arm_group>
    <arm_group_label>Proton group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Therapy</intervention_name>
    <arm_group_label>Proton group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of chordoma or chondrosarcoma.

          -  Patients must have no evidence of metastatic disease based on routine imaging (CT or
             MRI of the chest/abdomen/pelvis, bone scan, etc.)

          -  Patients must have an ECOG score equal to or less than 2.

          -  Age ≥ 18 years.

          -  Patients must be able to provide informed consent.

          -  Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3

          -  Women of child-bearing potential as long as she agrees to use a recognized method of
             birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.)
             Hysterectomy or menopause must be clinically documented.

          -  Tumors arising in the skull and spine.

        Exclusion Criteria:

          -  Prior or simultaneous malignancies within the past two years (other than cutaneous
             squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)

          -  Patients with the following histologies are excluded: melanoma , other soft tissue or
             bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other
             histologies.

          -  Pregnant women.

          -  Actively being treated on any other therapeutic research study.

          -  Tumors arising outside of the CNS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age 18 or greater</keyword>
  <keyword>No prior radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chondrosarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

